Molecular Changes in the Progression of Barrett's Oesophagus

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 2007 Aug 7

PMID 17675546

Citations 2

Authors

Edyta Zagorowicz

Janusz Jankowski

Affiliations

Soon will be listed here.

Abstract

Barrett's oesophagus is a frequent complication of gastro-oesophageal reflux disease predicting oesophageal adenocarcinoma. The majority of Barrett's patients will not develop cancer, so that specific methods of identification of those at risk are required. Recent molecular studies have identified a selection of candidate biomarkers that need validation in prospective studies. They reflect various changes in cell behaviour during neoplastic progression. The ASPECT trial in the UK aims to establish whether chemoprevention with aspirin and a proton pump inhibitor will reduce adenocarcinoma development and mortality in patients with Barrett's oesophagus. It will also validate biomarkers for progression and clinical response and further study disease pathogenesis.

Citing Articles

Management of Barrett's esophageal carcinoma.

Miyazaki T, Inose T, Tanaka N, Yokobori T, Suzuki S, Ozawa D Surg Today. 2013; 43(4):353-60.

PMID: 23283352 DOI: 10.1007/s00595-012-0468-2.

Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia.

Lee S, Han M, Lee K, Back S, Hwang D, Kim H PLoS One. 2012; 7(5):e37571.

PMID: 22629421 PMC: 3358277. DOI: 10.1371/journal.pone.0037571.

References

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Lord R, Salonga D, Danenberg K, Peters J, DeMeester T, Park J . Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000; 4(2):135-42. DOI: 10.1016/s1091-255x(00)80049-9. View

Kelloff G, Sigman C, Johnson K, Boone C, Greenwald P, Crowell J . Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9(2):127-37. View

Shirvani V, Kaur B, Omary M, Triadafilopoulos G . Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000; 118(3):487-96. DOI: 10.1016/s0016-5085(00)70254-x. View

Reid B, Levine D, Longton G, Blount P, Rabinovitch P . Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000; 95(7):1669-76. PMC: 1783835. DOI: 10.1111/j.1572-0241.2000.02196.x. View

Shaheen N, Crosby M, Bozymski E, Sandler R . Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology. 2000; 119(2):333-8. DOI: 10.1053/gast.2000.9302. View

Bani-Hani K, Martin I, Hardie L, Mapstone N, Briggs J, Forman D . Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000; 92(16):1316-21. DOI: 10.1093/jnci/92.16.1316. View

Weston A, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A . Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000; 95(8):1888-93. DOI: 10.1111/j.1572-0241.2000.02234.x. View

Eads C, Lord R, Kurumboor S, Wickramasinghe K, Skinner M, Long T . Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000; 60(18):5021-6. View

10.

Silberg D, Swain G, Suh E, Traber P . Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000; 119(4):961-71. DOI: 10.1053/gast.2000.18142. View

11.

Kawakami K, Brabender J, Lord R, Groshen S, Greenwald B, Krasna M . Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000; 92(22):1805-11. DOI: 10.1093/jnci/92.22.1805. View

12.

Sharma P . Barrett's esophagus: from process to outcomes. Am J Gastroenterol. 2001; 96(3):624-6. DOI: 10.1111/j.1572-0241.2001.03596.x. View

13.

Eads C, Lord R, Wickramasinghe K, Long T, Kurumboor S, Bernstein L . Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001; 61(8):3410-8. View

14.

Morris C, Armstrong G, Bigley G, Green H, Attwood S . Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001; 96(4):990-6. DOI: 10.1111/j.1572-0241.2001.03599.x. View

15.

Weston A, BANERJEE S, Sharma P, Tran T, Richards R, Cherian R . p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol. 2001; 96(5):1355-62. DOI: 10.1111/j.1572-0241.2001.03851.x. View

16.

Schnell T, Sontag S, Chejfec G, Aranha G, Metz A, OConnell S . Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001; 120(7):1607-19. DOI: 10.1053/gast.2001.25065. View

17.

Buttar N, Wang K, Sebo T, Riehle D, Krishnadath K, Lutzke L . Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001; 120(7):1630-9. DOI: 10.1053/gast.2001.25111. View

18.

Pepe M, Etzioni R, Feng Z, Potter J, Thompson M, Thornquist M . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93(14):1054-61. DOI: 10.1093/jnci/93.14.1054. View

19.

Wong D, Paulson T, Prevo L, Galipeau P, Longton G, Blount P . p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 2001; 61(22):8284-9. View

20.

Shay J, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33(5):787-91. DOI: 10.1016/S0959-8049(97)00062-2. View